[go: up one dir, main page]

DK590288D0 - Kemiske forbindelser - Google Patents

Kemiske forbindelser

Info

Publication number
DK590288D0
DK590288D0 DK590288A DK590288A DK590288D0 DK 590288 D0 DK590288 D0 DK 590288D0 DK 590288 A DK590288 A DK 590288A DK 590288 A DK590288 A DK 590288A DK 590288 D0 DK590288 D0 DK 590288D0
Authority
DK
Denmark
Prior art keywords
pellet
supernatant
fraction
components
new
Prior art date
Application number
DK590288A
Other languages
English (en)
Inventor
Alan G Barbour
Sven Bergstroem
Louis Magnarelli
Original Assignee
Symbicom Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8146053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK590288(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of DK590288D0 publication Critical patent/DK590288D0/da
Priority to DK590288A priority Critical patent/DK590288D0/da
Application filed by Symbicom Ab filed Critical Symbicom Ab
Priority to AT89912228T priority patent/ATE150318T1/de
Priority to DE68929565T priority patent/DE68929565D1/de
Priority to CA002001328A priority patent/CA2001328C/en
Priority to AT00125910T priority patent/ATE432988T1/de
Priority to EP00125910A priority patent/EP1092774B1/en
Priority to DE68929550T priority patent/DE68929550T2/de
Priority to AU44953/89A priority patent/AU639667B2/en
Priority to DE68929369T priority patent/DE68929369T2/de
Priority to AT93201345T priority patent/ATE212376T1/de
Priority to EP95203128A priority patent/EP0711563B1/en
Priority to EP89912228A priority patent/EP0445135B1/en
Priority to EP93201345A priority patent/EP0565208B1/en
Priority to PCT/DK1989/000248 priority patent/WO1990004411A1/en
Priority to DE68927891T priority patent/DE68927891T2/de
Priority to FI911964A priority patent/FI112366B/fi
Priority to NO91911602A priority patent/NO911602L/no
Priority to DK199100750A priority patent/DK175844B1/da
Priority to US08/137,175 priority patent/US5777095A/en
Priority to US08/079,601 priority patent/US5523089A/en
Priority to US08/262,220 priority patent/US6054296A/en
Priority to US08/264,036 priority patent/US6300101B1/en
Priority to US08/320,416 priority patent/US5582990A/en
Priority to US08/375,993 priority patent/US5688512A/en
Priority to US08/479,017 priority patent/US6143872A/en
Priority to US08/470,627 priority patent/US6203798B1/en
Priority to US08/466,393 priority patent/US6183986B1/en
Priority to US08/470,638 priority patent/US6509017B1/en
Priority to US08/471,019 priority patent/US6083722A/en
Priority to US08/588,637 priority patent/US7094391B1/en
Priority to PCT/US1997/000557 priority patent/WO1997026006A1/en
Priority to AU17470/97A priority patent/AU740048B2/en
Priority to EP97904758A priority patent/EP0876156A4/en
Priority to FI981624A priority patent/FI981624A7/fi
Priority to IL12532397A priority patent/IL125323A0/xx
Priority to JP9526117A priority patent/JP2000507209A/ja
Priority to ZA9700459A priority patent/ZA97459B/xx
Priority to NO983220A priority patent/NO983220L/no
Priority to US09/973,406 priority patent/US6814970B2/en
Priority to DK200401413A priority patent/DK200401413A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK590288A 1919-10-24 1988-10-24 Kemiske forbindelser DK590288D0 (da)

Priority Applications (40)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser
PCT/DK1989/000248 WO1990004411A1 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi
DE68927891T DE68927891T2 (de) 1988-10-24 1989-10-24 Fraktionen von BORELLA BURGDORFERI mit immunogener Wirkung
AU44953/89A AU639667B2 (en) 1988-10-24 1989-10-24 Immunogenically active fractions of borrelia burgdorferi
EP95203128A EP0711563B1 (en) 1988-10-24 1989-10-24 Substantially pure entire ospa protein free from other b. burgdorferi related material
CA002001328A CA2001328C (en) 1988-10-24 1989-10-24 Borrelia antigen
AT00125910T ATE432988T1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi ospa polypeptid zur immunisierung gegen lymeborreliose
EP00125910A EP1092774B1 (en) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA polypeptide for immunization against Lyme disease
DE68929550T DE68929550T2 (de) 1988-10-24 1989-10-24 Im Wesentlichen reines ganzes OspaA-Protein, frei von anderen B. burgdorferi-Materialien
AT89912228T ATE150318T1 (de) 1988-10-24 1989-10-24 Fraktionen von borella burgdorferi mit immunogener wirkung
DE68929369T DE68929369T2 (de) 1988-10-24 1989-10-24 DNS Fragmente, die für Borrelia burgdorferi OspA kodieren, Verfahren zur Herstellung von OspA Polypeptiden, und diagnostische Verfahren basierend auf diesen DNS Fragmenten
AT93201345T ATE212376T1 (de) 1988-10-24 1989-10-24 Dns fragmente, die für borrelia burgdorferi ospa kodieren, verfahren zur herstellung von ospa polypeptiden, und diagnostische verfahren basierend auf diesen dns fragmenten
DE68929565T DE68929565D1 (de) 1988-10-24 1989-10-24 Borrelia burgdorferi OspA Polypeptid zur Immunisierung gegen Lymeborreliose
EP89912228A EP0445135B1 (en) 1988-10-24 1989-10-24 Immogenically active fractions of borrelia burgdorferi
EP93201345A EP0565208B1 (en) 1988-10-24 1989-10-24 DNA fragments encoding OspA of Borrelia burgdorferi, method of preparation of OspA polypeptides and diagnostic methods based upon said DNA fragments
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
NO91911602A NO911602L (no) 1988-10-24 1991-04-23 Immunogent aktive fraksjoner av borrelia burgdorferi.
FI911964A FI112366B (fi) 1988-10-24 1991-04-23 Menetelmä organismin Borrelia burgdorferi OspA -polypeptidin ja sitä tuottavan organismin valmistamiseksi ja menetelmässä käytettäviä välineitä
US08/137,175 US5777095A (en) 1988-10-24 1992-10-22 Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US08/079,601 US5523089A (en) 1988-10-24 1993-06-22 Borrelia antigen
US08/262,220 US6054296A (en) 1988-10-24 1994-06-20 66 kDa antigen from Borrelia
US08/264,036 US6300101B1 (en) 1988-10-24 1994-06-22 Methods and compositions including a 13kD B. burgdorferi protein
US08/320,416 US5582990A (en) 1988-10-24 1994-10-03 DNA encoding borrelia burgdorferi OspA and a method for diagnosing borrelia burgdorferi infection
US08/375,993 US5688512A (en) 1988-10-22 1995-01-20 Borrelia antigen
US08/479,017 US6143872A (en) 1988-10-24 1995-06-06 Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US08/470,627 US6203798B1 (en) 1988-10-24 1995-06-06 Borrelia antigen
US08/466,393 US6183986B1 (en) 1988-10-24 1995-06-06 OspA DNA and lyme disease vaccine
US08/470,638 US6509017B1 (en) 1919-10-24 1995-06-06 66 KDA antigen from Borrelia
US08/471,019 US6083722A (en) 1988-10-24 1995-06-06 Borrelia antigen
US08/588,637 US7094391B1 (en) 1988-10-24 1996-01-19 Compositions and methods for administering Borrelia burgdorferi antigens
JP9526117A JP2000507209A (ja) 1988-10-24 1997-01-17 ボレリア・ブルグドフェリ（Ｂｏｒｒｅｌｉａ ｂｕｒｇｄｏｒｆｅｒｉ）抗原を投与するための組成物および方法
IL12532397A IL125323A0 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
PCT/US1997/000557 WO1997026006A1 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
AU17470/97A AU740048B2 (en) 1988-10-24 1997-01-17 Compositions and methods for administering borrelia burgdorferi antigens
EP97904758A EP0876156A4 (en) 1988-10-24 1997-01-17 COMPOSITIONS AND METHODS FOR THE APPLICATION OF ANTIGENS FOR BORRELIA BURGDORFERI
FI981624A FI981624A7 (fi) 1988-10-24 1997-01-17 Koostumukset ja menetelmät Borrelia burgdorferi antigeenien annostelem iseksi
ZA9700459A ZA97459B (en) 1988-10-24 1997-01-20 Composition and methods for administering borrelia burgdorferi antigens.
NO983220A NO983220L (no) 1988-10-24 1998-07-13 Sammensetninger og fremgangsmåter for å administrere Borrelia Burgdorferi-antigener
US09/973,406 US6814970B2 (en) 1988-10-24 2001-10-09 Methods and compositions including a 13 kD B. burgdorferi protein
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK590288A DK590288D0 (da) 1988-10-24 1988-10-24 Kemiske forbindelser

Publications (1)

Publication Number Publication Date
DK590288D0 true DK590288D0 (da) 1988-10-24

Family

ID=8146053

Family Applications (3)

Application Number Title Priority Date Filing Date
DK590288A DK590288D0 (da) 1919-10-24 1988-10-24 Kemiske forbindelser
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK199100750A DK175844B1 (da) 1988-10-24 1991-04-23 DNA fragment, der koder for et Borrelia burgdorferi OspA polypeptid, en vektor, en værtsmikroorganisme, en fremgangsmåde til fremstilling af OspA polypeptider samt en fremgangsmåde til diagnosticering af Borrelia burgdorferi infektion
DK200401413A DK200401413A (da) 1988-10-24 2004-09-17 OspA polypeptid, præparat omfattende OspA polypeptidet og anvendelse af OspA polypeptidet til fremstilling af et præparat til immunisering mod Lyme Disease

Country Status (10)

Country Link
US (6) US5523089A (da)
EP (4) EP0711563B1 (da)
AT (3) ATE212376T1 (da)
AU (1) AU639667B2 (da)
CA (1) CA2001328C (da)
DE (4) DE68929550T2 (da)
DK (3) DK590288D0 (da)
FI (1) FI112366B (da)
NO (1) NO911602L (da)
WO (1) WO1990004411A1 (da)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US6054296A (en) 1988-10-24 2000-04-25 Symbicom Ab 66 kDa antigen from Borrelia
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
WO1993008306A1 (en) * 1991-10-22 1993-04-29 Symbicom Aktiebolag Improvement in borrelia burgdorferi diagnosis and prophylaxis
US7094391B1 (en) * 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6300101B1 (en) 1988-10-24 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions including a 13kD B. burgdorferi protein
US5777095A (en) * 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
DE4015911A1 (de) * 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit
ZA907419B (en) * 1989-09-19 1991-07-31 Max Planck Gesellschaft Vaccine against lyme disease
US5470712A (en) * 1990-03-05 1995-11-28 Us Health Antigenic proteins of Borrelia burgdorferi
SG47447A1 (en) 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
ATE196425T1 (de) * 1990-07-06 2000-10-15 American Home Prod Impfstoff gegen die lyme-krankheit
CA2057536C (en) * 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
US5436000A (en) * 1991-01-11 1995-07-25 University Of Texas System Flagella-less borrelia
CA2110920A1 (en) * 1991-06-13 1992-12-23 Sinfu Tzeng Assay for the detection of specific ligands
US5324630A (en) * 1991-06-28 1994-06-28 The Regents Of The University Of California Methods and compositions for diagnosing lyme disease
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
ES2135411T3 (es) * 1991-08-15 1999-11-01 Smithkline Beecham Biolog Proteinas osp a de subgrupos de borrelia burgdorferi, genes codificantes y vacunas.
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
EP0620860A4 (en) * 1991-10-18 1997-05-02 Connaught Lab Preparation of recombinant borrelia proteins.
US5618533A (en) * 1992-02-11 1997-04-08 Yale University Flagellin-based polypeptides for the diagnosis of lyme disease
US5308753A (en) * 1992-02-20 1994-05-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for purifying and detecting IGM antibodies
US6303129B1 (en) * 1992-07-28 2001-10-16 Rx Technologies Production of borrelia burgdorferi vaccine, product produced thereby and method of use
BE1006728A3 (fr) * 1993-02-19 1994-11-29 Wallone Region Sondes d'acides nucleiques specifiques au spirochete borrelia burgdorferi.
US5656451A (en) * 1993-07-30 1997-08-12 Yale University OspE, OspF, and S1 polypeptides in borrelia burgdorferi
US6716591B1 (en) 1993-07-30 2004-04-06 Yale University B. burgdorferi polypeptides
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
EP0757556B1 (en) * 1994-04-11 2006-06-14 Wyeth Holdings Corporation Borrelia burgdorferi bacterin
US6087097A (en) * 1994-05-12 2000-07-11 Mayo Foundation For Medical Education And Research PCR detection of Borrelia burgdorferi
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
US6312907B1 (en) 1995-04-24 2001-11-06 The Texas A & M University System DbpA compositions and methods of use
US6248517B1 (en) 1995-04-24 2001-06-19 The Texas A & M University System Decorin binding protein compositions and methods of use
US6214355B1 (en) 1995-04-24 2001-04-10 Texas A & M University System DbpA compositions
AU6028396A (en) * 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
ZA964896B (en) 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
US6251405B1 (en) * 1995-06-07 2001-06-26 Connaught Laboratories, Inc. Immunological combination compositions and methods
US6045804A (en) * 1996-03-07 2000-04-04 Mayo Foundation For Medical Educational Research Method for detecting B. burgdorferi infection
EP0915977A1 (en) * 1996-05-08 1999-05-19 Yale University B. burgdorferi polypeptides expressed in vivo
US5846946A (en) * 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
DE19632862B4 (de) * 1996-08-14 2006-08-03 Mikrogen Molekularbiologische Entwicklungs-Gmbh Immunologisch aktive Proteine von Borrelia burgdorferi, dafür kodierende Nukleinsäuren sowie deren Verwendung in Testkits und als Impfstoffe
US6368603B1 (en) 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
WO1998058943A1 (en) * 1997-06-20 1998-12-30 Human Genome Sciences, Inc. Borrelia burgdorferi polynucleotides and sequences
US6902893B1 (en) 1997-06-20 2005-06-07 Gil H. Choi Lyme disease vaccines
ES2270523T3 (es) * 1997-06-30 2007-04-01 The Administrators Of The Tulane Educational Fund Antigenos de superficie y proteinas utiles en composiciones para la diagnosis y prevencion de la enfermedad de lyme.
AU8881198A (en) * 1997-09-10 1999-03-29 Symbicom A.B. P13 antigens from (borrelia)
US6610838B1 (en) 1997-09-10 2003-08-26 Symbicom Aktiebolag P13 antigens from Borrelia
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
GB9811219D0 (en) * 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
US6475492B1 (en) 1999-04-28 2002-11-05 The Administrators Of The Tulane Educational Fund Peptides and assays for the diagnosis of lyme disease
AU4800500A (en) * 1999-06-21 2001-01-09 Milkhaus Laboratory, Inc. Method for treatment of lyme disease
US6689364B2 (en) * 2000-03-21 2004-02-10 Tufts University Borrelia burgdorferi polypeptides and uses thereof
AU2001274068A1 (en) * 2000-06-02 2001-12-11 Zeptosens Ag Kit and method for determining a plurality of analytes
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
US20040033623A1 (en) * 2002-08-16 2004-02-19 Igenex, Inc. Assay for detection of antigen in bodily fluid
AU2003304145A1 (en) * 2002-10-18 2004-12-13 Macrogenics, Inc. Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
JP2006522808A (ja) 2003-04-02 2006-10-05 ザ ガバメント オブ ザ ユナイティド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービスィーズ コレステロール含有化合物およびボレリア・ブルグドルフェリに対する免疫原としてのそれらの使用方法
US20060051060A1 (en) * 2003-07-03 2006-03-09 Henry Dorovanessian Method and system for digitally recording broadcast content
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
US20060281139A1 (en) * 2005-05-23 2006-12-14 Viramed Biotech Ag Carrier and method for the detection of anti-borrelia antibodies and test kit for use in the diagnosis of Lyme borreliosis infections
US7663212B2 (en) 2006-03-21 2010-02-16 Infineon Technologies Ag Electronic component having exposed surfaces
US7541681B2 (en) * 2006-05-04 2009-06-02 Infineon Technologies Ag Interconnection structure, electronic component and method of manufacturing the same
MX2009004866A (es) 2006-11-03 2009-05-19 Schering Plough Ltd Vacuna para enfermedad de lyme canina.
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
US20110117131A1 (en) * 2008-04-09 2011-05-19 Ning Huang Production of OspA for Lyme Disease Control
JP5721620B2 (ja) 2008-05-02 2015-05-20 キャンサー・リサーチ・テクノロジー・リミテッドＣａｎｃｅｒ Ｒｅｓｅａｒｃｈ Ｔｅｃｈｎｏｌｏｇｙ Ｌｉｍｉｔｅｄ 免疫応答を刺激するための作製物および方法
US10722562B2 (en) 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
US20130011424A1 (en) 2010-03-09 2013-01-10 Timur ARTEMEV Polyepitope constructs and methods for their preparation and use
JP6227407B2 (ja) 2010-05-14 2017-11-08 バクスアルタ インコーポレイテッド Ｏｓｐａキメラおよびそのワクチンでの使用法
WO2012023033A2 (en) 2010-08-18 2012-02-23 Purdue Pharma L.P. Improved peptide immunogens
EP2622346A4 (en) 2010-09-27 2014-04-16 Univ Cornell METHOD FOR DIAGNOSING THE LYME DISEASE
WO2012047970A1 (en) * 2010-10-05 2012-04-12 Board Of Trustees Of Michigan State University Regulatory factors controlling oil biosynthesis in microalgae and their use
EP3682897A1 (en) 2012-07-27 2020-07-22 Baxalta GmbH Compositions comprising chimeric ospa molecules and methods of use thereof
WO2016134006A1 (en) * 2015-02-17 2016-08-25 Colorado State University Research Foundation High sensitivity method for early lyme disease detection
EA039370B1 (ru) 2016-04-14 2022-01-19 Мериал, Инк. Иммуногенная многодозовая композиция, содержащая антимикробный полиамидный консервант
WO2018227109A1 (en) 2017-06-08 2018-12-13 Colorado State University Research Foundation Differentiation of lyme disease and southern tick-associated rash illness
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
WO2023240124A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4981685A (en) * 1986-03-07 1991-01-01 Utah State University Foundation Bacterial extract vaccines for veterinary application
US4888276A (en) * 1986-06-26 1989-12-19 Minnesota Mining And Manufacturing Company Method and composition for the diagnosis of Lyme disease
US4721617A (en) 1986-08-14 1988-01-26 Regents Of The University Of Minnesota Vaccine against lyme disease
DE4015911A1 (de) 1989-09-19 1991-03-28 Max Planck Gesellschaft Impfstoff gegen die lyme-krankheit

Also Published As

Publication number Publication date
US6183986B1 (en) 2001-02-06
NO911602L (no) 1991-06-24
FI911964A0 (fi) 1991-04-23
EP0565208A1 (en) 1993-10-13
US5582990A (en) 1996-12-10
EP1092774A2 (en) 2001-04-18
DE68929369T2 (de) 2002-09-26
DE68927891T2 (de) 1997-10-02
EP0711563A1 (en) 1996-05-15
WO1990004411A1 (en) 1990-05-03
DE68927891D1 (de) 1997-04-24
DE68929550T2 (de) 2007-12-06
ATE150318T1 (de) 1997-04-15
DE68929565D1 (de) 2009-07-16
EP1092774A3 (en) 2001-04-25
EP0445135A1 (en) 1991-09-11
EP0711563B1 (en) 2007-01-17
AU639667B2 (en) 1993-08-05
AU4495389A (en) 1990-05-14
DE68929369D1 (de) 2002-03-14
DK75091D0 (da) 1991-04-23
EP0565208B1 (en) 2002-01-23
FI112366B (fi) 2003-11-28
EP1092774B1 (en) 2009-06-03
CA2001328C (en) 2005-12-13
DK200401413A (da) 2004-09-17
ATE432988T1 (de) 2009-06-15
EP0445135B1 (en) 1997-03-19
US5688512A (en) 1997-11-18
US6083722A (en) 2000-07-04
ATE212376T1 (de) 2002-02-15
CA2001328A1 (en) 1991-04-24
DK175844B1 (da) 2005-03-29
US5523089A (en) 1996-06-04
DE68929550D1 (de) 2007-03-08
US6203798B1 (en) 2001-03-20
NO911602D0 (no) 1991-04-23
DK75091A (da) 1991-06-12

Similar Documents

Publication Publication Date Title
DK590288D0 (da) Kemiske forbindelser
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
WO2000073316A3 (en) Virus immunologic determinants
KR970707153A (ko) 카텝신 02 프로테아제(cathepsin 02 protease)
EP0338767A3 (en) Novel recombinant and chimeric antibodies directed against a human adenocarcinoma antigen
HUP9800730A2 (hu) Expressziós rendszer heterológ antigének fúziós proteinként történő expresszáltatására
ES2137931T3 (es) Proteinas gdf-1 y uog-1.
ES2147178T3 (es) Dominio de union a cd2 del antigeno 3 asociado con la funcion linfocitica.
ATE387458T1 (de) Fas-antigenbindender ligand
EP0185076A4 (da)
Clezardin et al. Isolation of thrombospondin released from thrombinstimulated human platelets by fast protein liquid chromatography on an anion-exchange mono-q column
EP0331356A3 (en) Expression of hiv binding proteins
FI970428A0 (fi) Soluja, joissa on CD4-houkutusreseptoreita ja vastaavia molekyylejä ja menetelmiä
Takenaka et al. Royal jelly from Apis cerana japonica and Apis mellifera
FR2244539A1 (en) Tuberculin active proteins and peptides prepn - from tubercle bacillus
Lee-Huang A new preparative method for isolation of human erythropoietin with hydrophobic interaction chromatography
DE3853693D1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung.
PT85093A (fr) Vecteur viral et procede de preparation de adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a.
DE3788993D1 (de) Rekombinante Ligninase.
EP0345792A3 (en) Htlv-i / hiv-1 fusion proteins
WO1997026361A3 (en) Bacterial donor cell useful in conjugation
Petersen et al. Hydrophobic interaction chromatography used for purification of a Treponema Reiter ribonucleic acid antigen precipitating with antibodies in human syphilitic sera
RU96124779A (ru) Днк, кодирующая кератиназу bacilus licheniformis pwd-1
Vila et al. Action of thrombin of platelets. Characterization of total and membrane proteins. Platelet-fibrinogen interaction
SE9404066D0 (sv) Fusion proteins of immunopotentiating activity

Legal Events

Date Code Title Description
AHS Application shelved for other reasons than non-payment